Companies ›Healthcare ›038070.KQ

038070.KQ — KOSDAQ Biotechnology & Medical Research

Seoulin Bioscience Co Ltd

$5 030,00

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

1,58 %

Op margin

2,0 %

ROE

0,7 %

Net margin

3,0 %

Debt / equity

0,04

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Seoulin Bioscience Co Ltd is a South Korean company engaged in healthcare diagnostics, primarily generating revenue through the development and sale of diagnostic products and services.

Business. Seoulin Bioscience Co Ltd (038070.KQ) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. It is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic presence are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

0,7 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 038070.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 038070.KQ. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Seoulin Bioscience Co Ltd (038070.KQ) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models. It is listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic presence are not available.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

Seoulin Bioscience maintains a strong liquidity position, with a current ratio of 3.56, indicating the company can easily cover its short-term liabilities with its current assets. The company's liquidity_fpt score is high, supported by a cash and equivalents balance of KRW 13,743,417,930, which is a significant portion of its total assets. The company's debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal reliance on debt financing.

In terms of profitability, Seoulin Bioscience reported a net income of KRW 564,560,590 and an operating income of KRW 374,872,770 in the latest period. The return on equity (ROE) is 0.68%, and the return on assets (ROA) is 0.55%, both of which are below the industry median for biotechnology and medical research firms. This suggests the company is underperforming in terms of capital efficiency and asset utilization.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the company's exposure to market-specific risks, particularly in the healthcare diagnostics sector. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets or product lines.

Looking ahead, Seoulin Bioscience is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures are minimal, with a negative value of KRW -55,976,660, indicating a focus on cost control and asset optimization. The company's free cash flow of KRW 835,204,480 supports its ability to fund operations and potentially invest in future growth opportunities.

The risk assessment for Seoulin Bioscience indicates a low probability of dilution and no immediate liquidity concerns. The company's low debt levels and strong cash position reduce the likelihood of equity dilution through new financing. However, the company's low ROE and ROA suggest that it may need to improve its operational efficiency to sustain long-term growth. No recent filings or transcripts indicate significant changes in the company's strategic direction or financial health.

Key takeaways

Seoulin Bioscience has a strong liquidity position with a current ratio of 3.56 and a low debt-to-equity ratio of 0.04.
The company's profitability metrics, including ROE and ROA, are below industry medians, indicating underperformance in capital efficiency.
Revenue is concentrated in a single segment, with no geographic diversification disclosed, increasing market-specific risk.
The company is expected to maintain a stable revenue trajectory with minimal capital expenditures and a positive free cash flow.
The risk assessment indicates low liquidity and dilution risks, but the company may need to improve operational efficiency to sustain growth.

Bull / Bear case

Generated · model-assisted

BULL CASE · 1

The company faces low dilution and liquidity risks, providing a stable capital structure environment.

BEAR CASE · 3

Revenue declined at a 1.1% annual rate over four years, showing persistent top-line stagnation.

Return on invested capital is merely 0.43%, suggesting inefficient deployment of capital relative to peers.

Cash conversion ratio of 0.69 trails the 0.87 cohort median, reflecting weaker earnings quality.

In focus — financials by report

Annual

ANNUALFiled 2015-02-24

FY 2015 · Full-year highlights

Revenue KRW 80.54B; Operating income KRW 6.04B.

RevenueKRW 80.54B

Operating incomeKRW 6.04B

Net incomeKRW 15.59B

Free cash flowKRW 15.21B

EPS—

Operating cash flowKRW 8.92B

Financials

Income statement

RevenueKRW 80.54B

Gross profitKRW 21.10B

Operating incomeKRW 6.04B

Net incomeKRW 15.59B

Margins

Gross margin26.2%

Operating margin7.5%

Net margin19.4%

FCF margin18.9%

Balance sheet

Total assetsKRW 136.57B

Total liabilitiesKRW 61.71B

Total equityKRW 74.86B

Cash & equivalentsKRW 14.97B

Long-term debtKRW 15.74B

Cash flow

Operating cash flowKRW 8.92B

CapEx-KRW 1.67B

Free cash flowKRW 15.21B

SBC—

P&L flow · revenue → net income

Highlights

▍Revenue KRW 80.54B
▍Operating income KRW 6.04B
▍Net margin 19.4%

Valuation FY

Market price

$5 030,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$82.79B

Net cashⓘ

$10.13B

Current ratioⓘ

3.6

Debt / equityⓘ

0.0

ROAⓘ

0.5%

ROEⓘ

0.7%

Cash conversionⓘ

69.0%

CapEx / revenueⓘ

-0.3%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin2,0 %Above P75

Net Margin3,0 %Above P75

ROE0,7 %Above P75

Capex / Rev-0,3 %Above P75

D/E0,04Below median

Cash Conv0,69Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Seoulin Bioscience Co Ltd Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

038070.KQCanonical

KOSDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

2015-02-24 12:43 UTCEARNINGSAnnual results — FY 2015 Revenue KRW 80.54B · Net KRW 15.59B

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread